Interleukin-6 Expression and Stage, Location, And Degree Of Differentiation On Colorectal Cancer Patients

Muchizal Aqni; Fadhila Rianty

Authors

Muchizal Aqni RS Wahidin Sudirohusodo Makassar
Fadhila Rianty RS Wahidin Sudirohusodo Makassar

Keywords:

Colorectal Cancer, Interleukin-6, Cross-sectional Design, Tumor Stage

Abstract

Interleukin-6 (IL-6) is a type of inflammatory cytokine that mediates hematopoiesis and lymphocyte activation. Furthermore, recent studies showed that it has a role as a mediator of tumor progression. The expression of this cytokine correlated with tumor grade, poor survival, clinical stage of colorectal cancer, and metastasis. This allows IL-6 to be useful in diagnosis and predict the poor prognosis of colorectal cancer for treatment management to be carried out more aggressively. Also, Interleukin-6 is involved in colorectal cancer metastases because it is detected in the cell supernatants and serum of patients. However, it is not clear whether it is involved in the pathogenesis, formation, or metastasis of cancer. This study aimed to ascertain the expression of Interleukin-6 with a clinicopathological overview in colorectal cancer patients, specifically to determine its relationship with the stage, location, metastasis, and disease differentiation. This is an analytical observational study with a cross-sectional design to determine the relationship between Interleukin-6 expression and clinical features, stage, as well as degree of differentiation in colorectal cancer patients. Furthermore, this study was conducted in our institution from September 2019 to May 2020. 32 research subjects met the inclusion and exclusion criteria. Based on the analysis, it was shown that IL-6 expression has a significant relationship with the tumor stage (p=0.001) and differentiation (p=0,034). However, location do not show a significant relationship (p=0.098). IL-6 may be an important indicator for predicting the prognosis of colorectal cancer patients and could be a future therapeutic approach.

References

Marley, A. R. dan Nan, H. (2016) “Epidemiology of colorectal cancer.,” International journal of molecular epidemiology and genetics, 7(3), hal. 105–114. Tersedia pada: http://www.ncbi.nlm.nih.gov/pubmed/27766137.

Siegel, R. L. et al. (2017) “Colorectal cancer statistics, 2017,” CA: A Cancer Journal for Clinicians, 67(3), hal. 177–193. doi: 10.3322/caac.21395.

Torre, L. A. et al. (2015) “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, 65(2), hal. 87–108. doi: 10.3322/caac.21262.

Rasic, I. et al. (2018) “The Association of Simultaneous Increase in Interleukin-6, C Reactive Protein, and Matrix Metalloproteinase-9 Serum Levels with Increasing Stages of Colorectal Cancer,” Journal of Oncology, 2018, hal. 1–7. doi: 10.1155/2018/2830503.

Waldner, M. J., Foersch, S. dan Neurath, M. F. (2012) “Interleukin-6 - A key regulator of colorectal cancer development,” International Journal of Biological Sciences, 8(9), hal. 1248–1253. doi: 10.7150/ijbs.4614.

Mohamad, B. J. dan Zghair, F. A. (2019) “Interleukin-6 Expression in Colorectal Tumors in Iraqi Patients,” International Journal of Medical Research & Health Sciences, 8(4), hal. 1–8.

Wang, L. H. et al. (2004) “Transcriptional Inactivation of STAT3 by PPARγ Suppresses IL-6-Responsive Multiple Myeloma Cells,” Immunity, 20(2), hal. 205–218. doi: 10.1016/S1074-7613(04)00030-5.

Boyle, P. dan Leon, M. E. (2002) “Epidemiology of colorectal cancer,” British Medical Bulletin, 64(1), hal. 1–25. doi: 10.1093/bmb/64.1.1.

Lusikooy RE, S. S. (2013) “Karakteristik kanker kolorektal di Indonesia; Kajian Epidemiologi berbasis Rumah Sakit berdasarkan Data Seminar Nasional I Makassar Colorectal Cancer (MCC) 2011,” Majalah Ilmu Bedah Makassar, hal. 7–11.

Zeng, J. et al. (2017) “Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer,” World Journal of Gastroenterology, 23(10), hal. 1780. doi: 10.3748/wjg.v23.i10.1780.

Schneider, M. R. et al. (2000) “Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells,” Cancer Letters, 151(1), hal. 31–38. doi: 10.1016/S0304-3835(99)00401-2.

Wang, Y. C. et al. (2012) “Comparison of cancer incidence between China and the USA,” Cancer Biology and Medicine, 9(2), hal. 128–132. doi: 10.3969/j.issn.2095-3941.2012.02.009.

Hsu, C.-P. dan Chung, Y.-C. (2006) “Influence of interleukin-6 on the invasiveness of human colorectal carcinoma.,” Anticancer research, 26(6B), hal. 4607–14. Tersedia pada: http://www.ncbi.nlm.nih.gov/pubmed/17201185.

Yang, J. F. et al. (2016) “Colorectal cancer anatomic distribution patterns remain the same after sessile serrated adenoma/polyp considered cancer precursor: A 9-year comparison study from community-based endoscopy centers,” Journal of Gastrointestinal Oncology, 7(6), hal. 917–923. doi: 10.21037/jgo.2016.07.02.

Chung, Y.-C. dan Chang, Y.-F. (2003) “Serum interleukin-6 levels reflect the disease status of colorectal cancer,” Journal of Surgical Oncology, 83(4), hal. 222–226. doi: 10.1002/jso.10269.

Knüpfer, H. dan Preiß, R. (2007) “Significance of interleukin-6 (IL-6) in breast cancer (review),” Breast Cancer Research and Treatment, 102(2), hal. 129–135. doi: 10.1007/s10549-006-9328-3.

Mager, L. F. et al. (2016) “Cytokine-Induced Modulation of Colorectal Cancer,” Frontiers in Oncology, 6. doi: 10.3389/fonc.2016.00096.